XOMA (NASDAQ:XOMA) Given New $117.00 Price Target at HC Wainwright

XOMA (NASDAQ:XOMA) had its price target lifted by HC Wainwright from $74.00 to $117.00 in a research report report published on Thursday, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for XOMA’s Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($0.96) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at $0.60 EPS.

Several other research analysts have also weighed in on XOMA. SVB Leerink began coverage on shares of XOMA in a research note on Monday, April 29th. They set an outperform rating and a $40.00 price objective on the stock. Leerink Partnrs reissued an outperform rating on shares of XOMA in a research report on Monday, April 29th. Finally, StockNews.com raised shares of XOMA from a sell rating to a hold rating in a report on Wednesday.

XOMA Trading Down 2.2 %

NASDAQ:XOMA traded down $0.61 during trading hours on Thursday, hitting $27.21. 1,561 shares of the stock were exchanged, compared to its average volume of 20,466. The company has a market capitalization of $318.36 million, a P/E ratio of -7.10 and a beta of 0.93. The company has a quick ratio of 9.45, a current ratio of 9.45 and a debt-to-equity ratio of 1.39. The company’s 50 day moving average is $25.44 and its two-hundred day moving average is $24.69. XOMA has a twelve month low of $13.48 and a twelve month high of $30.36.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in XOMA. BNP Paribas Financial Markets raised its position in XOMA by 55.6% in the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,266 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of XOMA in the first quarter worth $212,000. Rhumbline Advisers boosted its holdings in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.